Multi-Model Consensus — 7 Categories, 5 Frontier LLMs
Scoring: Rank #1 = 10 pts, #2 = 9 … #10 = 1. Max = 50.
| # | Physician | Score | GPT-5.5 | GPT-5.4 | Opus | Sonnet | DeepSeek | In |
|---|---|---|---|---|---|---|---|---|
| 1 | Peter Attia | 50 | #1 | #1 | #1 | #1 | #1 | 5/5 |
| 2 | Nir Barzilai | 29 | #2 | #5 | #5 | #3 | — | 4/5 |
| 3 | David Sinclair | 26 | — | — | #3 | #2 | #2 | 3/5 |
| 4 | Mark Hyman | 24 | #9 | — | #2 | #5 | #4 | 4/5 |
| 5 | Andrea Maier | 23 | #3 | #3 | #4 | — | — | 3/5 |
| 6 | Valter Longo | 22 | — | #2 | — | #6 | #3 | 3/5 |
| 7 | Eric Topol | 12 | #10 | — | — | #4 | #7 | 3/5 |
| 8 | Luigi Fontana | 11 | #5 | #6 | — | — | — | 2/5 |
| 9 | Eric Verdin | 9 | — | #7 | #6 | — | — | 2/5 |
| 10 | Evelyne Bischof | 8 | — | #4 | #10 | — | — | 2/5 |
Scoring: Rank #1 = 10 pts … Max = 50.
| # | Doctor | Score | GPT-5.5 | GPT-5.4 | Opus | Sonnet | DeepSeek | In |
|---|---|---|---|---|---|---|---|---|
| 1 | Peter Attia | 39 | — | #2 | #1 | #1 | #1 | 4/5 |
| 2 | Andrea Maier | 27 | #3 | #1 | #2 | — | — | 3/5 |
| 3 | Nir Barzilai | 24 | #2 | #5 | — | #2 | — | 3/5 |
| 4 | Valter Longo | 20 | — | #4 | — | #6 | #3 | 3/5 |
| 5 | Mark Hyman | 19 | — | — | #5 | #5 | #4 | 3/5 |
| 6 | Evelyne Bischof | 16 | — | #3 | #3 | — | — | 2/5 |
| 7 | James Kirkland | 11 | #1 | #10 | — | — | — | 2/5 |
| 8 | Luigi Fontana | 11 | #5 | #6 | — | — | — | 2/5 |
| 9 | Eric Topol | 9 | — | #7 | — | — | #5 | 2/5 |
| 10 | David Sinclair | 9 | — | — | — | — | #2 | 1/5 |
Scoring: Rank #1 = 10 pts … Max = 50.
| # | Scientist | Score | GPT-5.5 | GPT-5.4 | Opus | Sonnet | DeepSeek | In |
|---|---|---|---|---|---|---|---|---|
| 1 | David Sinclair | 49 | #2 | #1 | #1 | #1 | #1 | 5/5 |
| 2 | Judith Campisi | 27 | #3 | #3 | #6 | — | #5 | 4/5 |
| 3 | Nir Barzilai | 26 | — | #2 | #3 | — | #2 | 3/5 |
| 4 | Valter Longo | 26 | #5 | #5 | — | #5 | #3 | 4/5 |
| 5 | Cynthia Kenyon | 24 | #1 | — | #4 | #4 | — | 3/5 |
| 6 | Steve Horvath | 22 | #4 | — | #2 | #9 | #7 | 4/5 |
| 7 | Brian Kennedy | 14 | #7 | #8 | — | #10 | #6 | 4/5 |
| 8 | Aubrey de Grey | 9 | — | #10 | — | #3 | — | 2/5 |
| 9 | Leonard Guarente | 8 | #6 | — | — | — | — | 1/5 |
| 10 | Jan van Deursen | 7 | — | — | — | — | #4 | 1/5 |
Scoring: Rank #1 = 10 pts … Max = 50.
| # | Course / Program | Score | GPT-5.5 | GPT-5.4 | Opus | Sonnet | DeepSeek | In |
|---|---|---|---|---|---|---|---|---|
| 1 | Healthy Longevity Medicine Society (HLMS) | 30 | #1 | #1 | #1 | — | — | 3/5 |
| 2 | A4M Fellowship (Anti-Aging & Regenerative) | 30 | #5 | #3 | #5 | #1 | — | 4/5 |
| 3 | Harvard Medical School CME | 29 | #10 | — | #2 | #2 | #1 | 4/5 |
| 4 | Buck Institute Programs | 29 | #7 | #5 | #7 | #4 | #3 | 5/5 |
| 5 | IFM Certification | 23 | #4 | — | #6 | #3 | #8 | 4/5 |
| 6 | NUS Healthy Longevity Programme | 21 | #6 | #2 | #4 | — | — | 3/5 |
| 7 | USC Leonard Davis School | 17 | #2 | #6 | #8 | — | — | 3/5 |
| 8 | American College of Lifestyle Medicine | 13 | #3 | — | — | #6 | — | 2/5 |
| 9 | Stanford CME / Center on Longevity | 12 | — | — | #3 | #9 | #9 | 3/5 |
| 10 | Coursera / Univ. Copenhagen | 8 | — | — | #10 | — | #4 | 2/5 |
Scoring: Rank #1 = 10 pts … Max = 50.
| # | Institution | Score | GPT-5.5 | GPT-5.4 | Opus | Sonnet | DeepSeek | In |
|---|---|---|---|---|---|---|---|---|
| 1 | Buck Institute for Research on Aging | 50 | #1 | #1 | #1 | #1 | #1 | 5/5 |
| 2 | Albert Einstein College of Medicine | 33 | #4 | #3 | #3 | #8 | #4 | 5/5 |
| 3 | Harvard / Paul F. Glenn Center | 31 | — | #6 | #2 | #4 | #2 | 4/5 |
| 4 | USC Leonard Davis School | 28 | #5 | — | #5 | #3 | #3 | 4/5 |
| 5 | Mayo Clinic Kogod Center on Aging | 22 | #3 | #4 | #9 | — | #6 | 4/5 |
| 6 | Salk Institute | 19 | #8 | — | #7 | #5 | #5 | 4/5 |
| 7 | National Institute on Aging (NIH) | 19 | #2 | #10 | — | #2 | — | 3/5 |
| 8 | NUS Centre for Healthy Longevity | 17 | #10 | #2 | #4 | — | — | 3/5 |
| 9 | Max Planck Institute for Biology of Ageing | 14 | #6 | — | #6 | — | #7 | 3/5 |
| 10 | Stanford Center on Longevity | 10 | #9 | — | — | #6 | #8 | 3/5 |
Scoring: Rank #1 = 10 pts … Max = 50.
| # | Clinic | Score | GPT-5.5 | GPT-5.4 | Opus | Sonnet | DeepSeek | In |
|---|---|---|---|---|---|---|---|---|
| 1 | Human Longevity Inc. | 48 | #1 | #1 | #1 | #1 | #3 | 5/5 |
| 2 | Peter Attia's Early Medical | 27 | — | — | #3 | #2 | #1 | 3/5 |
| 3 | Clinique La Prairie | 24 | #6 | — | #5 | #4 | #5 | 4/5 |
| 4 | Fountain Life | 18 | #2 | — | #2 | — | — | 2/5 |
| 5 | Chi Longevity | 15 | #4 | #3 | — | — | — | 2/5 |
| 6 | Biograph | 14 | #3 | #5 | — | — | — | 2/5 |
| 7 | Lanserhof | 13 | #7 | #6 | #7 | — | — | 3/5 |
| 8 | SHA Wellness Clinic | 13 | #8 | — | #6 | #6 | — | 3/5 |
| 9 | Sheba Longevity Center | 9 | — | #2 | — | — | — | 1/5 |
| 10 | Hooke London | 8 | — | #4 | #10 | — | — | 2/5 |
Scoring: Rank #1 = 10 pts … Max = 50.
| # | Contributor | Score | GPT-5.5 | GPT-5.4 | Opus | Sonnet | DeepSeek | In |
|---|---|---|---|---|---|---|---|---|
| 1 | Nir Barzilai | 38 | #5 | #2 | #3 | #4 | #3 | 5/5 |
| 2 | David Sinclair | 35 | #8 | #7 | #1 | #2 | #2 | 5/5 |
| 3 | Aubrey de Grey | 29 | #10 | #10 | #4 | #1 | #1 | 5/5 |
| 4 | Peter Attia | 26 | — | #4 | #2 | #4 | #5 | 4/5 |
| 5 | Cynthia Kenyon | 22 | #3 | — | #5 | #3 | — | 3/5 |
| 5 | Valter Longo | 22 | #9 | #3 | — | #5 | #4 | 4/5 |
| 7 | Steve Horvath | 17 | #4 | — | #7 | #5 | #8 | 4/5 |
| 8 | Judith Campisi | 16 | #4 | #6 | — | — | #4 | 3/5 |
| 9 | Andrea Maier | 13 | — | #1 | #8 | — | — | 2/5 |
| 10 | James Kirkland | 11 | #6 | #5 | — | — | — | 2/5 |
Across 7 categories and 5 frontier language models, several clear patterns emerge in the landscape of longevity medicine:
Peter Attia achieves a perfect 50/50 score as a longevity physician — every model ranked him #1 — and dominates the clinical categories. His book Outlive and rigorous evidence-based approach have made him the reference standard for longevity clinical practice.
David Sinclair dominates the scientific category (49/50) and appears prominently across contributors and physicians. His work on sirtuins, NAD+, and epigenetic reprogramming has shaped both public perception and research direction.
The Buck Institute achieves a perfect score (50/50) as an institution — the only standalone aging research institute in the world, it remains the consensus gold standard.
Human Longevity Inc. leads clinics (48/50), reflecting Craig Venter's genomics-first diagnostic model that defined the category.
Andrea Maier and Evelyne Bischof appear prominently in both the physician and doctor categories, reflecting their roles in building longevity medicine as a formal clinical discipline. Bischof co-founded the Healthy Longevity Medicine Society (HLMS), whose certification course ties for #1 among longevity medicine education programs.
Nir Barzilai emerges as the top contributor to longevity medicine overall (38/50), driven by his role in the TAME trial — the first attempt to have aging recognized as a treatable condition by the FDA — and decades of centenarian genetics research.
The term "longevity medicine" emerged as a distinct concept around 2020, representing a paradigm shift from reactive "anti-aging medicine" to proactive, biomarker-driven preventive care. While no single individual coined the term in a vacuum, Alex Zhavoronkov and Evelyne Bischof were among the earliest and most systematic proponents of longevity medicine as a formal clinical discipline.
In October 2020, Zhavoronkov published a Forbes article titled "Women in Longevity Medicine and the Rise of the Longevity Physician", defining longevity medicine as "advanced personalized preventative medicine powered by deep biomarkers of aging and longevity" and describing the emerging profession of the longevity physician. In December 2020, an "Introduction to Longevity Medicine for Physicians" course initiated by Zhavoronkov launched on Udemy, becoming one of the first structured educational programs in the field.
In January 2021, Zhavoronkov, Bischof, and Kai-Fu Lee published "Artificial intelligence in longevity medicine" in Nature Aging — a landmark paper proposing a framework for applying AI to extend human longevity and explicitly naming "longevity medicine" as a new discipline emerging from the convergence of AI, biomarkers, and geroscience.
In April 2021, Bischof, Scheibye-Knudsen, Siow, and Moskalev published "Longevity medicine: upskilling the physicians of tomorrow" in The Lancet Healthy Longevity, calling for formal medical education in longevity medicine and defining its scope for the clinical community.
Longevity medicine has evolved through distinct phases:
The American Academy of Anti-Aging Medicine (A4M), founded in 1992, created the first physician certification programs. This era was characterized by hormone replacement, supplements, and cosmetic interventions — often criticized for lack of rigorous evidence and conflation with wellness marketing.
The "Geroscience Hypothesis" — that targeting fundamental aging mechanisms could prevent multiple age-related diseases simultaneously — gained mainstream scientific acceptance. The TAME trial concept (targeting aging with metformin) proposed by Barzilai became a watershed moment, attempting to have aging itself recognized as an indication.
The convergence of AI-powered biomarkers, epigenetic clocks, senolytic therapies, and reprogramming science created the conditions for longevity medicine to emerge as a formal discipline. Key milestones include:
Longevity medicine is evolving rapidly along several trajectories:
The field is at an inflection point. The next decade will determine whether longevity medicine becomes a standard medical specialty — with board certification, insurance reimbursement, and regulatory frameworks — or remains a premium service. The evidence density building across AI biomarkers, geroscience trials, and clinical translation suggests the former is increasingly inevitable.